Sanofi India Ltd - 500674 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Life Insurance Corporation of India Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has received communication from its Registrar and Share Transfer Agent on loss of share certificate(s), details of which are enclosed: Sanofi India Ltd - 500674 - Appointment of Company Secretary and Compliance Officer
As required under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors of the Company at its meeting held on 26th October 2021, approved appointment of Ms. Radhika Shah as Company Secretary and Key Managerial Personnel with effect from 1st November 2021. Pursuant to Regulation 6 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Ms. Radhika Shah will also be the Compliance Officer with effect from 1st November 2021 in place of Mr. Vaibhav Karandikar. Detailed announcement is enclosed. Please take the above information on record.
Sanofi India net profit at Rs 530 crore in September quarter
Sanofi India board in its meeting held on July 27 had approved a transaction for slump sale and transfer of its nutraceuticals business to Universal Nutriscience for a consideration of Rs 587 crore. Sanofi India Ltd - 500674 - Unaudited Financial Results For The Quarter And Nine Months Ended 30Th September 2021
We refer to our letter dated 13th October 2021 informing you of our Board Meeting that was scheduled today. The Meeting of Board of Directors commenced at 1.30 p.m. and concluded at 04.00 p.m. The Board approved unaudited financial results for the quarter and nine months ended 30th September 2021. Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose a copy of the unaudited financial results for the quarter and nine months ended 30th September 2021 approved at this Meeting along with a copy of the Limited Review Report duly signed by the Auditors of the Company. Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has issued duplicate share certificates in lieu of the original share certificates reported lost/misplaced, details of which are enclosed. Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has received communication from its Registrar and Share Transfer Agent on loss of share certificate(s), details of which are enclosed. Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has issued duplicate share certificates in lieu of the original share certificates reported lost/misplaced, details of which are enclosed Sanofi India Ltd - 500674 - Shareholding for the Period Ended September 30, 2021
Sanofi India Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2021. For more details, kindly Click here Sanofi India Ltd - 500674 - Board Meeting Intimation for Unaudited Financial Results For The Quarter And Nine Months Ended 30Th September 2021 (Q3).
Sanofi India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/10/2021 ,inter alia, to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the meeting of the Board of Directors of the Company will be held on Tuesday, 26th October 2021; inter alia to consider the unaudited financial results for the quarter and nine months ended 30th September 2021 (Q3).